We are pleased to share the latest Community Letter issued by Roche, providing an update on their ongoing efforts in Spinal Muscular Atrophy (SMA) in 2024. The letter includes the latest developments on risdiplam and Roche’s SMA clinical development program.
Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities.
Denmark has achieved a major milestone in SMA advocacy!
On 28 August 2024, after years of tireless efforts, the country secured access to SMA treatment for much of the community, including adults.
We are happy to share the latest Community Statement issued by Biogen about the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).